骨髓纤维化与B细胞急性淋巴细胞白血病CD19 CAR-T细胞治疗无应答相关
本研究对61例患者CAR-T治疗前后骨髓活检及54例原发B-ALL样本进行全转录组分析、网硬蛋白纤维化评估和CD3 T细胞浸润检测,发现无应答者治疗前即富集纤维化相关通路且骨髓纤维化水平显著高于完全缓解者,高纤维化与更差总生存相关。
要点
- 无应答者CAR-T治疗前骨髓即富集纤维化、细胞外基质及AP1、TGF-β3相关通路。
- 临床网硬蛋白评估和AI辅助数字图像评分均显示无应答者骨髓纤维化显著高于完全缓解者。
- 高水平骨髓纤维化与CAR-T治疗后更低总生存相关。
核心结论
- 骨髓纤维化是介导B-ALL对CD19 CAR-T细胞治疗无应答的新机制。
- 临床常用的骨髓纤维化定量检测可重新用于识别无应答高风险患者。
- 与骨髓纤维化相关的基因和通路是提高疗效的潜在靶点。
研究设计与样本
- 对61例患者CAR-T治疗前后骨髓核心活检行全转录组分析、网硬蛋白纤维化评估和CD3 T细胞浸润检测。
- 另对54例原发B-ALL样本进行相同分析。
主要发现
- 纤维化、细胞外基质发育及相关转录因子AP1和TGF-β3通路在无应答者中于CAR-T治疗前即已富集并上调。
- 临床网硬蛋白评估和AI辅助数字图像评分均显示无应答者骨髓纤维化水平显著高于完全缓解者。
- CD3+ T细胞在无应答者中呈浸润降低趋势。
- 无应答者CAR-T治疗前纤维化水平显著高于原发B-ALL。
- 高水平纤维化与CAR-T治疗后更低总生存相关。
临床怎么用
- 临床常用的骨髓纤维化定量检测可重新用于确定无应答高风险患者。
- 与骨髓纤维化相关的基因和通路是提高应答的潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone marrow (BM) stromal microenvironment in determining response to CAR T-cell therapy has been understudied. We performed whole transcriptome analysis, reticulin fibrosis assessment and CD3 T-cell infiltration on BM core biopsies from pre- and post-CAR timepoints for 61 patients, as well as on a cohort of 54 primary B-ALL samples. Pathways of fibrosis, extracellular matrix development, and associated transcription factors AP1 and TGF-β3, were enriched and upregulated in nonresponders (NR) even prior to CAR T cell therapy. NR showed significantly higher levels of BM fibrosis compared to complete responders by both clinical reticulin assessment and AI-assisted digital image scoring. CD3+ T cells showed a trend toward lower infiltration in NR. NR had significantly higher levels of pre-CAR fibrosis compared to primary B-ALL. High levels of fibrosis were associated with lower overall survival after CAR T-cell therapy. In conclusion, BM fibrosis is a novel mechanism mediating nonresponse to CD19-directed CAR T-cell therapy in B-ALL. A widely used clinically assay for quantitating myelofibrosis can be repurposed to determine patients at high risk of non-response. Genes and pathways associated with BM fibrosis are a potential target to improve response.
引用
- Anil J, Alnemri A, Lytle A, et al. Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia. Am J Hematol. 2023. PMID: 37718626. doi:10.1002/ajh.27098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。